These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 17690032

  • 1. Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.
    Yang YJ, Li LX, He Q, Fan H, Jin ZK, Lang R, Kou JT, Li P, Xie DH, Chen DZ.
    Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):376-8. PubMed ID: 17690032
    [Abstract] [Full Text] [Related]

  • 2. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 3. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ, Chen DZ, Li LX, Kou JT, Lang R, Jin ZK, Han DD, He Q.
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [Abstract] [Full Text] [Related]

  • 4. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus.
    Bäckman L, Reisaeter AV, Wramner L, Ericzon BG, Salmela K, Brattström C.
    Clin Transplant; 2006 Jun; 20(3):336-9. PubMed ID: 16824151
    [Abstract] [Full Text] [Related]

  • 5. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G.
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [Abstract] [Full Text] [Related]

  • 6. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ.
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [Abstract] [Full Text] [Related]

  • 7. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus.
    Casas-Melley AT, Falkenstein KP, Flynn LM, Ziegler VL, Dunn SP.
    Pediatr Transplant; 2004 Aug; 8(4):362-6. PubMed ID: 15265163
    [Abstract] [Full Text] [Related]

  • 8. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation.
    Campbell MS, Rai J, Kozin E, Bloom RD, Markmann JF, Olthoff KM, Shaked A, Rajender Reddy K.
    Clin Transplant; 2007 Aug; 21(3):377-84. PubMed ID: 17488388
    [Abstract] [Full Text] [Related]

  • 9. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [Abstract] [Full Text] [Related]

  • 10. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients.
    Nair S, Eason J, Loss G.
    Liver Transpl; 2003 Feb; 9(2):126-9. PubMed ID: 12548505
    [Abstract] [Full Text] [Related]

  • 11. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
    Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH.
    J Heart Lung Transplant; 2007 Oct; 26(10):998-1003. PubMed ID: 17919619
    [Abstract] [Full Text] [Related]

  • 12. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
    Balfour IC, Srun SW, Wood EG, Belsha CW, Marshall DL, Ferdman BR.
    J Heart Lung Transplant; 2006 May; 25(5):518-22. PubMed ID: 16678029
    [Abstract] [Full Text] [Related]

  • 13. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation.
    Zaghla H, Selby RR, Chan LS, Kahn JA, Donovan JA, Jabbour N, Genyk Y, Mateo R, Gagandeep S, Sher LS, Ramicone E, Fong TL.
    Aliment Pharmacol Ther; 2006 Feb 15; 23(4):513-20. PubMed ID: 16441472
    [Abstract] [Full Text] [Related]

  • 14. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors.
    Di Benedetto F, Di Sandro S, De Ruvo N, Spaggiari M, Montalti R, Ballarin R, Cappelli G, Gerunda GE.
    J Clin Gastroenterol; 2009 Mar 15; 43(3):280-6. PubMed ID: 19057397
    [Abstract] [Full Text] [Related]

  • 15. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 16. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.
    Peddi VR, Jensik S, Pescovitz M, Pirsch J, Adler SH, Thistlethwaite JR, Vincenti F, Cohen DJ.
    Clin Transplant; 2005 Feb 15; 19(1):130-6. PubMed ID: 15659146
    [Abstract] [Full Text] [Related]

  • 17. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.
    J Heart Lung Transplant; 2005 Dec 15; 24(12):2129-36. PubMed ID: 16364861
    [Abstract] [Full Text] [Related]

  • 18. Replacing calcineurin inhibitors with mTOR inhibitors in children.
    Sindhi R, Seward J, Mazariegos G, Soltys K, Seward L, Smith A, Kosmach B, Venkataramanan R.
    Pediatr Transplant; 2005 Jun 15; 9(3):391-7. PubMed ID: 15910398
    [Abstract] [Full Text] [Related]

  • 19. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation.
    Forgacs B, Merhav HJ, Lappin J, Mieles L.
    Transplant Proc; 2005 May 15; 37(4):1912-4. PubMed ID: 15919502
    [Abstract] [Full Text] [Related]

  • 20. Initial single-center experience with sirolimus after lung transplantation.
    Lischke R, Simonek J, Matousovic K, Stolz AJ, Schützner J, Vojácek J, Burkert J, Davidová R, Pafko P.
    Transplant Proc; 2006 Nov 15; 38(9):3006-11. PubMed ID: 17112886
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.